Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience

被引:0
作者
Yilmaz, Mukaddes [1 ]
Basak, Mustafa [2 ]
Ozyukseler, Deniz Tataroglu [3 ]
Yildirim, Mahmut Emre [4 ]
Arik, Zafer [5 ]
Salman, Mehmet Coskun [6 ]
Gultekin, Murat [6 ]
Akgor, Utku [7 ]
Inci, Bediz Kurt [8 ]
Gurler, Fatih [9 ]
Yucel, Kadriye Bir [10 ]
Savas, Gozde [10 ]
Onan, Mehmet Anil
Sunar, Veli [12 ]
Meydanli, Mehmet Mutlu [11 ,13 ]
Yazici, Ozan
Ozet, Ahmet [10 ]
机构
[1] Sivas Cumhuriyet Univ, Dept Med Oncol, Fac Med, Sivas, Turkiye
[2] Gazi Osman Pasa Univ, Dept Med Oncol, Fac Med, Tokat, Turkiye
[3] Fethi Sekin State Hosp, Dept Med Oncol, Elazig, Turkiye
[4] Dr Lutfi Kirdar Kartal Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye
[5] Hacettepe Univ, Dept Med Oncol, Canc Inst, Ankara, Turkiye
[6] Hacettepe Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[7] Ankara Numune Training & Res Hosp, Dept Gynecol Oncol, Ankara, Turkiye
[8] Kirsehir Training & Res Hosp, Dept Med Oncol, Kirsehir, Turkiye
[9] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Dept Med Oncol, Ankara, Turkiye
[10] Gazi Univ, Dept Med Oncol, Fac Med, Ankara, Turkiye
[11] Gazi Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[12] Aydin Ataturk State Hosp, Dept Med Oncol, Aydin, Turkiye
[13] Med Pk Hosp, Dept Gynecol Oncol, Gaziantep, Turkiye
来源
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY | 2023年
关键词
Interval debulking; neoadjuvant chemotherapy; ovarian carcinoma; primary debulking; CANCER; SURVIVAL; CYTOREDUCTION; OUTCOMES;
D O I
10.5505/tjo.2023.3883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVE The aim of the study is to compare treatment outcomes of the patients with federation of gynecology and obstetrics stages III and IV ovarian carcinomas, who underwent interval debulking surgery after neoadjuvant chemotherapy (NACT), and patients who underwent adjuvant chemotherapy after primary debulking surgery (PDS). METHODS Patients from four centers (n=183) were retrospectively evaluated. Of the patients, 91 (50%) were in the PDS group and 92 (50%) in the NACT group. RESULTS In the NACT group patients have advanced age, poor performance status, high levels of CA125, and advanced disease stage compared with the PDS group (p<0.050). Of the patients receiving NACT, 14 (15%) had a complete response, and 68 (74%) had a partial response. The R0 rate was higher in the PDS group (p=0.018). In univariate analysis, poor prognostic factors affecting OS were NACT in the treatment protocol (p<0.001), poor performance status (p<0.001), advanced age (<70 vs. >= 70, p=0.002), advanced clinical stage (p=0.042), and localization of the tumor with the largest diameter outside the omentum and ovary at the time of diagnosis (p=0.029). In the multivariate analysis, the presence of NACT (HR: 2.30, 95% CI: 1.25-4.23, p=0.007) and poor performance (HR: 2.52, 95% CI: 1.18-5.10, p=0.017) were independent poor prognostic factors for OS. CONCLUSION In the study, OS was better in the PDS group than in the NACT group. This result was thought to be associated with the NACT group having more disadvantageous characteristics (advanced age, poor performance, high CA125 level, advanced stage, etc.).
引用
收藏
页码:323 / 332
页数:10
相关论文
共 50 条
  • [41] Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
    Xingyu Liu
    Yingjun Zhao
    Xiaofei Jiao
    Yang Yu
    Ruyuan Li
    Shaoqing Zeng
    Jianhua Chi
    Guanchen Ma
    Yabing Huo
    Ming Li
    Zikun Peng
    Jiahao Liu
    Qi Zhou
    Dongling Zou
    Li Wang
    Qingshui Li
    Jing Wang
    Shuzhong Yao
    Youguo Chen
    Ding Ma
    Ting Hu
    Qinglei Gao
    Journal of Ovarian Research, 16
  • [42] Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
    Yoneoka, Yutaka
    Ishikawa, Mitsuya
    Uehara, Takashi
    Shimizu, Hanako
    Uno, Masaya
    Murakami, Takashi
    Kato, Tomoyasu
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (05)
  • [43] Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer
    Lee, Jessica
    Curtin, John P.
    Muggia, Franco M.
    Pothuri, Bhavana
    Boyd, Leslie R.
    Blank, Stephanie V.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 55 - 63
  • [44] Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602
    Onda, Takashi
    Satoh, Toyomi
    Saito, Toshiaki
    Kasamatsu, Takahiro
    Nakanishi, Toru
    Nakamura, Kenichi
    Wakabayashi, Masashi
    Takehara, Kazuhiro
    Saito, Motoaki
    Ushijima, Kimio
    Kobayashi, Hiroaki
    Kawana, Kei
    Yokota, Harushige
    Takano, Masashi
    Takeshima, Nobuhiro
    Watanabe, Yoh
    Yaegashi, Nobuo
    Konishi, Ikuo
    Kamura, Toshiharu
    Yoshikawa, Hiroyuki
    EUROPEAN JOURNAL OF CANCER, 2016, 64 : 22 - 31
  • [45] Advanced ovarian yolk sac tumor: upfront surgery or neoadjuvant chemotherapy followed by interval debulking?
    Zhang, Xinyue
    Yang, Jie
    Xiang, Yang
    Pan, Lingya
    Wu, Ming
    Cao, Dongyan
    Yang, Jiaxin
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (01) : 99 - 105
  • [46] Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Sioulas, Vasileios D.
    Schiavone, Maria B.
    Kadouri, David
    Zivanovic, Oliver
    Roche, Kara Long
    O'Cearbhaill, Roisin
    Abu-Rustum, Nadeem R.
    Levine, Douglas A.
    Sonoda, Yukio
    Gardner, Ginger J.
    Leitao, Mario M., Jr.
    Chi, Dennis S.
    GYNECOLOGIC ONCOLOGY, 2017, 145 (01) : 15 - 20
  • [47] Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center
    Mueller, Jennifer J.
    Zhou, Qin C.
    Iasonos, Alexia
    O'Cearbhaill, Roisin E.
    Alvi, Farah A.
    El Haraki, Amr
    Eriksson, Ane Gerda Zahl
    Gardner, Ginger J.
    Sonoda, Yukio
    Levine, Douglas A.
    Aghajanian, Carol
    Chi, Dennis S.
    Abu-Rustum, Nadeem R.
    Zivanovic, Oliver
    GYNECOLOGIC ONCOLOGY, 2016, 140 (03) : 436 - 442
  • [48] Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer
    Cowan, Renee A.
    Chi, Dennis S.
    Fagotti, Anna
    Scambia, Giovanni
    ONCOLOGY-NEW YORK, 2017, 31 (06): : 453 - +
  • [49] After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer A National Cancer Database Study
    Seagle, Brandon-Luke L.
    Graves, Stephen
    Strohl, Anna E.
    Shahabi, Shohreh
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (08) : 1610 - 1618
  • [50] Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?
    Menczer, Joseph
    Usviatzov, Irena
    Ben-Shem, Erez
    Golan, Abraham
    Levy, Tally
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2011, 22 (03) : 183 - 187